Post Exposure Treatment With Doxycycline for the Prevention of Relapsing Fever
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00237016|
Recruitment Status : Completed
First Posted : October 12, 2005
Last Update Posted : October 24, 2008
Abstract Background Tick-Borne Relapsing Fever (TBRF) is an acute febrile illness. In Israel, TBRF is caused by Borrelia persica and is transmitted by Ornithodoros tholozani ticks. We examined the safety and efficacy of a post exposure treatment policy to prevent TBRF.
Methods In a double blind, placebo controlled trial 93 healthy volunteers with suspected tick exposure (51 with bite signs and 42 contacts) were randomly assigned to receive either Doxycycline (200 mg for the first day and 100mg/d for 4 days) or placebo, approximately 2 days after contact. Blood smears were examined for Borrelia at inclusion and during fever rise. Serology for Lyme disease cross- reactivity and PCR for Borrelia GlpQ gene were also performed. Cases of TBRF were defined as subjects having fever and a positive blood smear.
|Condition or disease||Intervention/treatment||Phase|
|Relapsing Fever, Tick-Borne Jarisch Herxheimer Reaction||Drug: doxycycline treatment||Phase 2 Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||140 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Post Exposure Treatment With Doxycycline for the Prevention of Relapsing Fever|
|Study Start Date :||April 2002|
|Study Completion Date :||April 2003|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00237016
|Israel Defence Forces|
|Tel Hashomer, Israel|
|Principal Investigator:||Tal Hasin, MD||Medical corps, Israel Defence Forces|